Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14243MR)

This product GTTS-WQ14243MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14243MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13198MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ10544MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12076MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ331MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ14820MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ12106MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ8212MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW